Related Experiment Video

Updated: Aug 11, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.3K

Estrogen related receptor alpha: Potential modulator of age-related macular degeneration

Fatima Massare Somers1, Goldis Malek2

  • 1Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA.

Current Opinion in Pharmacology
|March 6, 2024
PubMed

Insights

Estrogen-related receptor alpha (ESRRA) plays a key role in age-related macular degeneration (AMD) pathogenesis. Targeting ESRRA signaling may offer a novel therapeutic strategy for treating this blinding disease.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Genetics

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss.
  • Understanding AMD's underlying mechanisms is crucial for developing effective treatments.
  • Estrogen-related receptor alpha (ESRRA) is implicated in several AMD-associated pathways.

Purpose of the Study:

  • To review the role of ESRRA in the ocular posterior pole during aging and AMD.
  • To highlight ESRRA as a potential molecular target for AMD therapies.
  • To discuss the therapeutic potential of targeting ESRRA signaling.

Main Methods:

  • Literature review of studies on ESRRA and AMD.
  • Analysis of ESRRA's role in ocular aging and AMD pathogenesis.
  • Evaluation of existing data on ESRRA signaling pathway targeting.

Main Results:

  • ESRRA regulates multiple pathogenic pathways relevant to AMD.
  • ESRRA's specific role in the aging ocular posterior pole and AMD is underexplored.
  • Evidence suggests ESRRA signaling is a viable therapeutic target.

Conclusions:

  • ESRRA is a significant molecular target in AMD pathobiology.
  • Targeting ESRRA represents a promising therapeutic avenue for AMD.
  • Further research into ESRRA signaling is warranted for AMD treatment development.

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K
A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration09:24

A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration

Published on: March 10, 2023

1.6K

Related Concept Videos

The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...